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INTRODUCTION
In  its  decade  in  existence,  commercial  RNA  interference 
(RNAi) therapeutics development has seen great financial 
volatility. The causes of this volatility are broadly shared with 
what has been observed on other technology frontiers such 
as gene therapy in the case of drug development, with the 
amplitude of the volatility magnified or moderated by macro-
economic factors. Volatility poses challenges especially for 
financially exposed small biotechnology companies, the core 
translational force of the industry, to establish the platform 
and develop drugs in a process that takes at least 15 years 
to bear fruits in the form of approved drugs and depends on 
the complex interactions between a diverse set of investors. 
Even small disruptions can have big repercussions leading 
to both euphoria and capitulation which can be equally dam-
aging to the long-term health of a sector.
This commentary is directed at companies already involved 
in  RNAi  therapeutics  development  or  those  interested  in 
entering the space. By analyzing the forces that shape the 
business of RNAi therapeutics at the start of 2012 it aims 
to uncover key opportunities for value creation. It may also 
help investors identify related investment opportunities and 
inventors commercialize their intellectual property (IP). For a 
review of the fundamental business case for RNAi therapeu-
tics, the reader is referred to an earlier article on the topic.1
RNAi THERAPEUTICS BUSINESS TRENDS IN  
HISTORICAL PERSPECTIVE
The business of RNAi therapeutics has just entered its fourth 
phase. The first, discovery phase (2002–05) was defined by 
the early adopters of RNAi as a therapeutic modality follow-
ing the discovery of RNAi in human cells.2 These were small, 
risk-taking  biotechnology  companies  such  as  Ribozyme 
Pharmaceuticals  (aka  Sirna  Therapeutics),  Atugen  (aka 
Silence Therapeutics) and Protiva (aka Tekmira). As much 
as they may have believed in the potential of RNAi thera-
peutics, their strategic reorientation was also a gamble on a 
technology with considerable technical uncertainties in order 
to turn around declining business fortunes by leveraging their 
nucleic acid therapeutics know-how to become leaders in a 
potentially disruptive technology. For example, exploration of 
in vivo gene knockdown had only just begun, not to speak 
of knockdown in larger animals following systemic delivery. 
This phase also saw the founding of Alnylam Pharmaceutical 
based on the idea of cornering the IP on the molecules that 
mediate RNAi (RNAi triggers) so that it may finance its own 
drug development by collecting a toll from all those engaged 
in RNAi therapeutics.
Until  then,  larger  pharmaceutical  companies  (“Big 
Pharma”) saw the value of RNAi largely as a research tool 
only. This, however, changed quickly when a few of them, 
including Medtronic, Novartis, and Merck, were seen by their 
peers to take an interest in RNAi as a therapeutic modality. 
The situation seemed reminiscent of monoclonal antibodies 
which had just established themselves as the major value 
creator in the pharmaceutical industry, but where Big Pharma 
was thought to be paying the price for having watched from 
the sidelines for too long. Another factor for Big Pharma’s 
surging RNAi therapeutics interest, the defining feature of 
the second, boom phase of RNAi therapeutics (2005–08), 
was the impending patent cliff and the hope that the technol-
ogy would mature in time to soften its financial impact.
A  bidding  war,  largely  for  access  to  potentially  gate-
keeping RNAi trigger IP erupted. Most notably, Merck and 
Roche paid US$1.1B for acquiring Sirna Therapeutics and 
US$300M+  for  a  limited  platform  license  from  Alnylam, 
respectively. These deals were only rivaled in attention by 
the award of a Nobel Prize to Andrew Fire and Craig Mello 
for their seminal discovery of double-stranded RNA (dsRNA) 
as the trigger of RNAi. The industry naturally did not mind 
the attention and in some cases fanned the fire by raising 
unrealistic expectations. This atmosphere also gave rise to 
controversial publications in high-profile journals which lent 
credence to the mistaken notion that the technical barriers to 
exploiting the RNAi trigger IP would be low.3,4 Consequently, 
most Big Pharma companies had a stake in the technology. 
Yet, the US$2.5B–3.5B in investments largely failed to formu-
late sound strategies for the real technical challenges such 
as delivery. Symptomatic for the times, the financial markets 
similarly failed to realize the value of truly enabling technolo-
gies: in the 2 weeks following the publication of a seminal 
paper on systemic small interfering RNA (siRNA) delivery 
by Protiva (now Tekmira) and Alnylam on 26 March 2006,5 
Alnylam’s share price would decline by over 10%.
It is therefore perhaps not surprising that this period of high 
expectations and blockbuster deals was followed by general 
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backlash (2008–2011), the financial consequences of which 
were exacerbated by global economic turmoil and health-
care rationing in the West. Big Pharma quickly realized their 
mistake of putting IP before enablement as they scrambled 
to scout for delivery technologies and found the majority of 
them not to live up to their claims.6 Roche, a year after their 
IP license from Alnylam, felt compelled to pay US$125M for 
Dynamic PolyConjugates from Mirus Bio, one of the more 
promising and differentiated delivery technologies, for which, 
however, significant risks related to translation into organ-
isms beyond rodents and manufacturing/scale-up remained. 
Contributing to buyer’s remorse was the ageing and rapidly 
eroding gate-keeping potential of the RNAi trigger IP that 
had been the focus of their original investments.
As much as delivery, it was the potential of certain RNAi for-
mulations to stimulate innate immunity that caused much of 
the scientific angst that contributed to the deteriorating busi-
ness sentiment in 2008.7,8 It almost came to be assumed that 
an in vivo RNAi efficacy claim was in fact an innate immuno-
stimulatory artefact. Importantly, this suspicion extended to 
the preclinical data that formed the rationale for the industry’s 
lead clinical candidates in wet age-related macular edema 
(Acuity/Opko’s  Cand5,  Merck/Allergan’s  Sirna-027/AGN-
745,  Quark/Pfizer’s  PF-4523655)9,10  and  respiratory  viral 
infection (Alnylam’s ALN-RSV01),11 approaches which inci-
dentally did not involve specific delivery chemistries. Mak-
ing matters worse still, innate immune stimulation is a safety 
issue. Although today innate immunostimulatory potential is 
widely considered to be manageable through chemical modi-
fication and choice of RNAi trigger structure, the reputational 
damage persists.
Suffering from RNAi-specific scientific and credibility issues 
and with first drug approvals still years away, RNAi therapeu-
tics was among the first to feel the cost-cutting axe at com-
panies like Pfizer, Merck, Abbott Labs, and Roche which all 
started to suffer from patent expirations, drug approval and 
productivity issues, worsening drug reimbursement climates, 
and the general loss of confidence in their innovative abili-
ties. Particularly the exit of Roche from in-house RNAi thera-
peutics development sent shockwaves through the industry. 
Having invested heavily in the technology only 2–3 years ago 
and  being  considered  an  innovation  bellwether  within  Big 
Pharma, Roche’s decision in late 2010 found a number of 
imitators among Big Pharma and has been functioning as a 
major barrier to new investments in RNAi therapeutics.
The backlash, however, also had cleansing effects which 
form the basis for the 4th, recovery phase of RNAi therapeu-
tics (2011–present). As a result of the financial restrictions 
and increased scientific scrutiny, there has been an overall 
increase  in  the  quality  of  the  science.  RNAi  therapeutics 
has also become less of a target for the quick-rich biotech 
schemes that constantly chase the next hot area in drug 
development. This quality shift is most evident in the evo-
lution of the RNAi therapeutics clinical pipeline which has 
become more and more populated with candidates based 
on sound scientific rationales, especially in terms of delivery 
approaches and anti-immunostimulatory strategies. For the 
recovery, however, to firmly take root and for the long-term 
health of the industry, it is important for the current clinical 
dataflow to bring back investors.
RNAi THERAPEUTICS ASSETS
One measure for the health of an industry is in accounting 
its assets. These are also at the center of business activity. 
Because drugs are the ultimate objective of RNAi therapeu-
tics and because of the significant de-risking that occurs dur-
ing drug development, the clinical and late-stage preclinical 
pipeline  weighs  heavy.  Equally  important  at  this  relatively 
early stage are the technologies that enable candidate devel-
opment and drive platform efficiencies. These technologies 
need to be protected by patents or trade secrets for individ-
ual companies to capture their full value.
RNAi therapeutics development pipeline. As of the 2008 
review,1 there were eight candidates in clinical development 
(Table 1). What is noticeable is that most of them were local 
RNAi approaches that today would most likely not enter devel-
opment due to uncertain scientific rationale or safety: naked 
delivery, in some cases with unmodified synthetic RNAi trig-
gers  (Cand5,  Sirna-027,  RTP-801i,  ALN-RSV01, TD-101), 
liposomal  delivery  of  a  DNA-directed  RNAi  (ddRNAi)  can-
didate which could have been predicted to be inadequate 
for antiviral applications and was all but assured to cause 
immune stimulation (NucB1000),12 or first-generation ddRNAi 
expression systems subsequently13 found to frequently cause 
cellular toxicity (rHIV-shI-TAR-CCR5RZ; possibly NucB1000). 
Not surprisingly, many of these programs were either termi-
nated,  or  their  future  development  is  doubtful.  Among  the 
latter,  there  is  hope  that  Quark/Pfizer’s  PF-4523655  and 
Alnylam’s ALN-RSV01 can still make it to market as long as 
they show appropriate safety and efficacy even though their 
value to RNAi therapeutics would be limited given the wide-
spread skepticism about their mechanism of action.
Since 2008, the development pipeline has not only grown 
in size (18 active clinical candidates today), but more impor-
tantly it has improved in quality concomitant with a shift from 
local to systemic delivery: 7 of the 14 new clinical candidates 
since 2008 were delivered systemically, compared to only 1 
of the 8 before. This is largely the result of the clinical entry 
of  the  most  advanced  systemic  delivery  platforms,  stable 
nucleic acid lipid particles (SNALP) and AtuPLEX. SNALP 
alone accounts for six clinical candidates (ALN-VSP02, TKM-
ApoB, ALN-TTR01, TKM-PLK1, ALN-PCS02, TKM-EBOLA) 
and one more is expected to enter the clinic in the near future 
(ALN-TTR02).
Given that the value of a given drug candidate is dynamic 
and can dramatically change with each new data point—such 
as a clinical trial result or even change in regulatory policy—
it is beyond the scope of this commentary to determine the 
market value of the RNAi development pipeline. Some candi-
dates, however, have been licensed which makes their market 
value easier to assess. Quark Pharmaceuticals for example 
has been quite successful in licensing its compounds. As of 31 
December 2010, Pfizer had invested $52.5M in PF-4523655 
which is in late phase II development for wet age-related mac-
ular edema and diabetic macular edema. Quark moreover is 
eligible to receive substantial future milestones and royalties.14 
Still, the value of PF-4523655 has become highly uncertain 
after phase II study results suggested that PF-4523655 faces 
an uphill battle before it can be a commercially viable drug.  
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Quark also sold an option for an exclusive license to its sec-
ond-most advanced candidate, QPI-1002, then in phase I for 
acute kidney injury and delayed graft function, for a remark-
able US$10M fee to Novartis. The market value of the only 
other  partnered  candidate  in  clinical  development,  ALN-
RSV01, has decreased considerably as its target population 
has shrunk drastically and after Alnylam’s partners for this 
drug candidate, Kyowa Hakko and Cubist Pharmaceuticals, 
have distanced themselves from it despite having invested 
more than US$35M in upfront alone.
The remaining value of the clinical pipeline largely rests on 
three oncology candidates (ALN-VSP, Atu027, TKM-PLK1) 
and  the  SNALP-enabled  ALN-PCS02  for  hypercholester-
olemia  and  ALN-TTR01/02  for  transthyretin  amyloidosis. 
This judgment is based on delivery that has been de-risked 
to some extent for these candidates, almost nonexistent tar-
get risks for three of them (TTR, PLK1, PCS02), and the fact 
that they all represent highly differentiated approaches for 
diseases of considerable unmet medical needs. Moreover, 
there  exist  early  biomarker  opportunities  for  two  of  them 
(TTR, PCS). Should these biomarker read-outs demonstrate 
effective target gene knockdown in their phase I studies, their 
value  would  increase  considerably,  possibly  pegging  their 
upfront partnering value in the high double-digit millions with 
Table 1  RNAi therapeutics clinical pipeline
Year of  
IND/CTA
 
Candidate
 
Indication
 
Target
 
Delivery
2004 Cand5 Wet AMD, diabetic macular edema VEGF Intravitreal needle injection (retina; local)
2004 Sirna-027/AGN-745 Wet AMD  VEGF-R1 Intravitreal needle injection (retina; local)
2005 ALN-RSV01 RSV infection Viral RNA Inhalation of unformulated siRNAs  
(lung epithelium; local)
2007 DGFi Acute kidney injury, delayed  
graft function
p53 Intravenous naked siRNA (proximal 
tubule cells; systemic)
2007 PF-4523655 Wet AMD, diabetic macular edema RTP801/REDD1 Intravitreal needle injection (retina; local)
2007 rHIV-shl-TAR-
CCR5RZ
HIV infection Viral RNA and host factors Lentiviral (hematopoietic stem cells;  
ex vivo)
2007 NucB1000 Hepatitis B viral infection HBV RNAs Liposomal plasmid (hepatocytes;  
systemic)
2008 TD101 Pachyonychia congenita Mutant keratin Intradermal needle injection (skin; local)
2008 Therapeutic vaccine Metastatic melanoma Immunoproteasome Electroporation (autologous monocytes; 
ex vivo)
2008 Excellair Asthma Syk kinase Inhalation of unformulated siRNAs  
(lung epithelium; local)
2008 CALAA-01 Nonresectable or metastatic solid  
tumors
M2 subunit of ribonucleotide 
reductase
RONDEL (solid tumor cells; systemic)
2008 ALN-VSP02 Liver cancer, cancer with liver  
involvement
VEGF, KSP SNALP liposome (hepatocytes;  
systemic)
2009 Atu027 Advanced solid tumors PKN3 AtuPLEX lipoplex (vascular endothelial 
cells; systemic)
2009 QPI-1007 Chronic nerve atrophy, nonarteritic  
ischemic optic neuropathy
Caspase 2 Intravitreal needle injection
2009 SYL040012 Intraocular pressure and glaucoma β-Adrenergic receptor 2 Eye drop (ciliary epithelial cells; local)
2009 TKM-ApoB Hypercholesterolemia Apolipoprotein B SNALP liposome (hepatocytes;  
systemic)
2009 bi-shRNAfurin/
GMCSF
Ovarian cancer, advanced  
melanoma
Furin Electroporation plasmid (autologous 
tumor samples; ex vivo)
2009 ALN-TTR01 Transthyretin amyloidosis Transthyretin SNALP liposome (hepatocytes;  
systemic)
2010 siG12D LODER Operable pancreatic ductal  
adenocarcinoma
Mutated KRAS LODER local drug elution
2010 TKM-PLK1 Solid cancers and lymphoma Polo-like kinase 1 SNALP liposomal (solid tumor cells; 
systemic)
2011 CEQ508 Familial adenomatous polyposis/
colon cancer prevention
β-Catenin Bacterial (mucosal layer of small and 
large intestine; oral)
2011 ALN-PCS02 Hypercholesterolemia PCSK9 SNALP liposome (hepatocytes;  
systemic)
2011 TKM-EBOLA Ebola infection (biodefense) Viral RNA SNALP liposome (hepatocytes and  
phagocytes; systemic)
Select preclinical candidates
  2012 (est.) RXI-109 Dermal scarring CTGF Intradermal needle injection (skin; local)
  2012 (est.) To be named HIV infection CCR5 Lentiviral transduction transduction  
(hematopoietic stem cells; ex vivo)
Abbreviations: AMD, age-related macular edema; CTGF, connective tissue growth factor; GMCSF, granulocyte-macrophage colony-stimulating factor; HBV, 
hepatitis B virus; KSP, kinesin spindle protein; PKN3, protein kinase N3; RSV, respiratory syncytial virus; shRNA, small hairpin RNA; siRNA, small interfering 
RNA; SNALP, stable nucleic acid lipid particles; VEGF, vascular endothelial growth factor.Molecular Therapy–Nucleic Acids
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the potential to generate substantially more revenues down-
stream. In the case of ALN-VSP and Atu027, early clinical 
data are already supportive of further development with the 
sponsors hoping to license these compounds in 2012.
Although  having  only  just  entered  clinical  development, 
TKM-EBOLA  may  actually  be  the  pipeline  asset  with  the 
highest net present value in the industry. This is because 
the full development of this biodefense candidate is being 
funded under a US$140M contract from the US Department 
of Defense. This contract allows Tekmira to not only earn 
incentive fees and profit from eventual stockpiling contracts, 
but also to develop the candidate in a way that broadly ben-
efits the platform on which it was built. Among the other pre-
clinical pipeline candidates, RXi Pharmaceutical’s RXI-109 
for  dermal  scarring,  and  Calimmune’s  ddRNAi  candidate 
for HIV deserve special mention based on their promising 
preclinical results,15 differentiation, and potential to blaze the 
trail for their respective self-delivering rxRNA and lentiviral 
ddRNAi platforms.
Enabling  technologies.  As  indicated  by  the  evolution  of 
the RNAi therapeutics product pipeline, it is the underlying 
technologies, foremost delivery, that are the major value driv-
ers. Other technologies, however, also add value by reducing 
adverse event risk, and in the case of RNAi trigger innova-
tion by opening up new therapeutic frontiers.
Delivery: one cell/tissue type, many indications. The pres-
ent expansion of the SNALP-based pipeline reflects a fun-
damental  principle  of  RNAi  therapeutics:  once  a  delivery 
technology is found suitable for knocking down genes in a 
given cell/tissue type, any gene can be targeted in that cell/
tissue  type  with  the  possible  applications  only  limited  by 
our exploding understanding of disease genetics (Table 2). 
SNALP,  Tekmira’s  PEG-stabilized  monolamellar  liposomes 
that  encapsulate  the  RNAi  trigger  payload  in  its  aqueous 
interior and which are neutrally charged at physiologic pH, 
is furthest developed for knocking down genes expressed in 
the liver, particularly hepatocytes.5 Solid tumor cells,16 sites of 
tissue inflammation, and phagocytic cells,17 however, are also 
suitable targets for SNALP due to their relative accessibility 
and/or natural propensity to take up nanosized particles.
With the caveat that there is sequence-dependent variabil-
ity, results from the SNALP-based trials with TKM-ApoB and 
ALN-VSP02 suggest that the SNALP formulations that were 
developed initially have potential for a few indications with 
less  stringent  tolerability  and  cost  requirements.  Improve-
ments in the efficacy and tolerability of SNALP over the last 
5 years,18 however, have significantly widened applicability 
through an expected 100- to 1,000-fold improvement in the 
therapeutic index, and further enhanced the competitive pro-
file of SNALP by reducing cost and treatment frequencies.
Symbolizing the value shift from RNAi triggers to delivery, 
Alnylam, which once relied on its RNAi trigger IP for its indus-
try-leading position, has been sued by Tekmira for scheming 
to unlawfully gain control and ownership over SNALP tech-
nology  and  otherwise  causing  damage  to Tekmira’s  com-
petitive position. Somewhat benefitting from this gridlock in 
SNALP  is  the  industry’s  second-most  advanced  systemic 
delivery technology, AtuPLEX by Silence Therapeutics. This 
multilamellar,  positively  charged,  lipid-based  formulation 
has proven useful for knocking down genes in the vascular 
endothelium in small and large animal models.19 The phar-
macokinetic and safety data that emerges from the ongoing 
Atu027 trial (e.g., ASCO 2011 poster presentation) indicate 
this also likely to be the case in humans. With applications 
particularly in oncology (antiangiogenesis) and acute inflam-
matory conditions (the vascular endothelium as a barrier to 
inflammatory cell infiltration), this technology has garnered 
increased partnership interest. Positively charged lipoplexes, 
in this case delivered by intravesical instillation, may also be 
useful for knocking down genes in the superficial layers of 
the bladder, including malignancies, as suggested by pre-
clinical data from Marina Biotech.20
Besides these and other lipid-based delivery technologies, 
there are a number of polymer and conjugate delivery tech-
nologies in earlier development. What started with largely 
negatively  charged  RNAi  triggers  complexed  to  positively 
charged polymers, an approach frequently associated with 
toxicities,21 polymers appear to be more promising as neutrally 
charged polyconjugates.22 Especially the smaller conjugates 
may be suited for gene knockdown in tissues not accessible 
to the larger lipid-based formulations. Manufacturing chal-
lenges and biodegradability issues, however, could be caus-
ing delays in their clinical translation. This appears to be the 
case for the Dynamic PolyConjugates for which Roche paid 
US$125M in 2008, but which Arrowhead Research recently 
acquired for single-digit million US dollars.23
Smaller  than  polyconjugates,  simple  conjugates  such 
as  the  GalNAc-siRNAs  (target  organ:  liver)  developed  by 
Alnylam may similarly reach a wider range of target cells/
tissues and could also be amenable to subcutaneous admin-
istration. Potency improvements, however, are required to 
render  them  competitive  with  the  more  complex  formula-
tions for systemic applications when the target cell/tissue is 
shared. It is in local/localized applications that similar small 
conjugates currently have most utility. A first such program is 
about to enter clinical development with RXi Pharmaceuti-
cal’s intradermally injected self-delivering rx-RNA RXI-109 for 
dermal scarring. Ocular, central nervous system (intraparen-
chymal, intrathecal) and respiratory (epithelial) applications 
may similarly benefit from simple conjugate solutions.
The RNAi trigger versus delivery debate is more balanced 
in ddRNAi technology. This is because delivery technologies 
can be directly borrowed from the field of gene therapy, with 
particularly  adeno-associated  virus  and  lentiviral  delivery 
Table 2  Tissues/cell types amenable to therapeutic RNAi today
Tissue/Cell type Delivery
Liver (hepatocytes, but also other cell types) SNALP
Vascular endothelial cells AtuPLEX
Solid tumor cells SNALP
Phagocytic cells, including antigen presenting cells SNALP
Skin Self-delivering 
rxRNAs
Hematopoietic stem cells Lentivirus
CNS, eye AAV, lentivirus
Abbreviations: AAV, adeno-associated virus; CNS, central nervous  
system; RNAi, RNA interference; SNALP, stable nucleic acid lipid  
particles. 
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well suited for a number of central nervous system,24 ocular,25 
and  hematopoietic  stem  cell-related  applications.15  Con-
versely, because ddRNAi is intended for gene silencing over 
extended periods of time following a single administration, 
and adverse reactions due to ddRNAi trigger activity cannot 
easily be reversed, ddRNAi trigger safety is paramount.13
Some of the delivery technologies above can also be used 
for ex vivo delivery. Here, the delivery challenge is essentially 
reduced to a tissue culture problem by RNAi treating the tar-
get cells outside the body using transfection, electroporation, 
or viral transduction, before (re-)introducing them into the 
patient. This approach holds particular promise for stem cell-
based therapeutics15 and therapeutic cancer vaccines.26
In  summary,  albeit  delivery  technologies  of  clinical  and 
commercial maturity are still relatively few in number, today’s 
delivery capabilities already allow for a number of high-quality 
RNAi therapeutics opportunities. This is because each deliv-
ery technology, once found to be suitable for gene knock-
down in a given cell/tissue type, can be rapidly expanded 
to  many  target  genes  and  applications.  Control  over  and 
access to these technologies is critical for RNAi therapeutics 
platform success.
RNAi triggers: potency matters, but value also in safety 
and new functionalities. One of the main developments in 
the RNAi trigger field has been the realization that many 
RNAs with dsRNA elements can induce RNAi gene silenc-
ing at least to some degree.27 Together with the weaken-
ing  of  Alnylam’s  RNAi  trigger  IP  estate  in  the  course  of 
the Kreutzer–Limmer (KL) and Tuschl patent prosecutions, 
choice and access to RNAi triggers has become less rate-
limiting than it was once thought of. It also means that work-
ing around somebody else’s IP estate alone does not easily 
compensate for deficiencies in scientific performance, espe-
cially knockdown potency which normally determines both 
the maximal degree and duration of the knockdown. Conse-
quently, non-Tuschl RNAi triggers should be at least equal 
in potency, if not superior, or offer additional advantages in 
safety and functionality.
In terms of potency, a single asymmetric instead of sym-
metrical 3′ overhangs on the guide strand has been found 
to improve on the knockdown efficacy of Tuschl siRNAs.28 
Potency can also be improved by applying thermodynamic 
design  rules  such  as  the  Zamore  rules  to  which  Silence 
Therapeutics has an exclusive license.29 Although the Dicer-
substrate RNAi triggers had once been proposed not only to 
fall outside of Alnylam’s RNAi trigger patent estate, but also 
to be more potent than Tuschl siRNAs,30 they may actually be 
a more appropriate example for the value of functional differ-
entiation by facilitating certain delivery strategies31 and poten-
tially also by extending the duration of gene silencing.32
Synthetic small hairpin RNAs can either function as Dicer-
substrate RNAs or also be smaller in size, yet still trigger RNAi 
(e.g., SomaGenics).32 These single-molecule RNAs have the 
benefit of increased thermodynamic stability which may be 
exploited for the manufacture of RNAi triggers with increased 
dsRNA  yield  than  conventional  two-stranded  siRNAs33  as 
well as delivery approaches which require single-stranded 
phases  during  the  delivery  journey.  Shorter  small  hairpin 
RNAs should also be less prone to induce innate immunity 
and interfere with endogenous small RNA processing. The 
latter attributes also apply to the first-generation asymmet-
ric  siRNAs  (asiRNA)  by  Biomolecular Therapeutics  which 
are  characterized  by  shorter  double-stranded  elements 
than those in conventional siRNAs.34 RXi Pharmaceutical’s 
sd-rxRNAs have even shorter double-stranded elements, a 
feature the company claims to be critical for crossing hydro-
phobic lipid bilayers during delivery. Nevertheless, because 
the success rate of finding potent RNAi triggers may drop 
noticeably  for  RNAi  triggers  with  such  short  dsRNA  ele-
ments,  these  structures  should  be  preferentially  contem-
plated in applications where they can add unique delivery or 
safety benefits.
The structural flexibility of RNAi triggers has also been 
exploited for increased functionality by having them target 
more  than  one  gene  (“multitargeting”). This  is  particularly 
valuable for treating complex diseases or where resistance 
is an issue (cancer, viral infections). Multitargeting is already 
being pursued in ALN-VSP02 and Tekmira’s Ebola program 
which involve the inclusion of several conventional siRNAs in 
a given formulation,16 but it can also be achieved for exam-
ple  by  using  three-  or  four-stranded  designs,  both  Dicer-
substrate and non Dicer-substrate, in which the individual 
strands guide the cleavage of distinct targets.35 Tekmira has 
recently licensed a three-stranded RNAi trigger design from 
Halo-Bio.
Although certainly adding to functionality, two RNAi trigger 
structures exploiting RNAi trigger structural diversity, immu-
nostimulatory siRNAs (e.g., Alnylam)36 and single-stranded 
RNAi triggers (e.g., ISIS Pharmaceuticals)37 run counter to 
two core principles of RNAi in Man. First, it was the Nobel-
Prize winning insight by Fire and Mello that dsRNA, and not 
for example single-stranded antisense RNA, is the trigger 
in RNAi. Second, the discovery of RNAi in mammals was 
based on the use of shorter dsRNAs that would not stimulate 
the nonspecific interferon response. It therefore remains to 
be seen whether the potency disadvantage (single-stranded 
RNAi)  and  safety  liability  (immunostimulatory  siRNAs)  of 
these triggers can be compensated for by their unique deliv-
ery attributes (single-stranded RNAi) or any anticancer, anti-
viral, or antiangiogenic effect of immunostimulatory siRNAs.
Unlike in synthetic RNAi triggers, innovation in ddRNAi 
trigger  design  has  somewhat  stalled,  particularly  in  the 
commercial and translational arenas, with most groups still 
employing first-generation minimal small hairpin RNAs driven 
by U6 and H1 Pol-III promoters. With safety remaining a con-
cern for these systems,13 and the causes of toxicity still to be 
fully identified, there is considerable value to be created by 
establishing alternative ddRNAi expression systems.
Tools  to  minimize  RNAi-related  adverse  event  risk.  The 
challenges of drug development do not stop with hitting the 
target. In a risk-averse regulatory environment, even theo-
rized or minor safety signals in preclinical studies can lead to 
substantial delays in the approval process. The value of tech-
nologies that minimize adverse event risk is therefore not only 
in protecting patient safety, but also in avoiding regulatory 
surprises. In RNAi therapeutics, such technologies can be 
categorized into those that address acute toxicity and those 
that deal with the risks associated with their long-term use.
Acute immune responses from activating innate immune 
receptors or the complement system is commonly considered Molecular Therapy–Nucleic Acids
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the next biggest scientific challenge besides delivery.8 Indeed, 
RNAi-related “flu-like symptoms” with inflammatory cytokine 
elevations have been observed in a number of clinical tri-
als (e.g., TKM-ApoB, NucB1000, CALAA-01),12 and activa-
tion of the alternative complement pathway was seen in the 
Atu027 trial. Although the clinical importance of such obser-
vations can vary considerably, it is necessary to improve on 
that record. Fortunately, understanding and mitigating, if not 
abolishing acute immune responses has been one of the 
most fertile areas of RNAi therapeutics research in recent 
years. We now understand most of the relevant nucleic acid 
structural  parameters  (e.g.,  dsRNA  length,  GU-rich  ele-
ments) and chemical modifications (e.g., 5′-triphosphates, 
2′-O-methyl), as well as the innate immune receptors (TLR3, 
7, 8; RIG-I; PKR) and cell types by which such activation may 
occur. Consequently, it is possible to adjust the RNAi trigger 
structure and, in the case of synthetic RNAi triggers, apply 
chemical modifications to minimize acute immune stimula-
tion risk, a prediction which can then be tested in predic-
tive assays.38 While capitalizing on this progress by licensing 
related IP has proven difficult, companies like Tekmira have 
created  brand  value  by  establishing  themselves  as  early 
adopters and experts in this area.8
Adverse side-effects stemming from the ability of siRNAs 
to function as microRNAs by dampening the expression of 
often hundreds of off-target genes is a safety concern espe-
cially in administering an RNAi therapeutic over extended 
periods of time (microRNA-type off-targeting).39 Similar to 
innate immune stimulation, progress in tackling this technical 
challenge has been swift over the last 5 years. Approaches 
to minimizing such off-targeting include bioinformatics which 
considers potential interactions between the seed element of 
an siRNA with the genome-wide repertoire of 3′-UTRs during 
the in silico stage of RNAi trigger selection, as well as chemi-
cal and structural modifications that can essentially eliminate 
passenger strand-mediated off-targeting (e.g., by passenger 
strand 5′ blocking or by shortening the length of the pas-
senger  strand)34,40  and  considerably  reduce  guide  strand-
mediated off-targeting by penalizing seed-only   interactions 
of a guide strand without compromising its ability to recog-
nize (on-)targets via more extensive base-pairing (e.g., by 
including  2′-O-methyl,  unlocked  nucleic  acid-modifications 
in  the  seed).41,42 With  the  help  of  standard  genome-wide 
expression tools, the effect of these strategies can now be 
routinely assessed and demonstrate that substantial reduc-
tions in off-targeting can be achieved by implementing the 
above strategies.42
It should be added, however, that although such advanced 
technology tools for minimizing microRNA-type off-targeting 
exist  and  bioinformatic  approaches  are  widely  applied  at 
the in silico stage of the RNAi trigger selection, the practical 
part of the RNAi selection and optimization process is still 
dominated by potency and the abrogation of immune stimu-
lation. This is partly also due to the difficulty of interpreting 
what the modulation of dozens of off-target genes means in 
toxicological terms, and maybe also a concern that too much 
information, for example theoretical concerns arising from 
expression changes of a gene that has been linked to can-
cer, could cause delays in a risk-averse regulatory climate. 
Of note, genome-wide off-targeting has received much less 
attention in the older antisense therapeutics field despite it 
being of equal importance to that field.
Toxicity due to interference with the functions of endog-
enous gene silencing as a result of competition for shared 
factors is another type of potential toxicity that is more likely 
to manifest itself over the long-term than at the time that 
the RNAi therapeutic is administered. This type of toxicity is 
mostly a concern for strategies that harness the endogenous 
RNAi/microRNA pathway upstream of RNA-induced silenc-
ing complex (e.g., synthetic Dicer-substrates, most ddRNAi 
approaches),13  although  perturbations  due  to  competition 
have  been  detected  by  sensitive  gene  expression  analy-
sis with siRNAs, too.43 Currently, the best strategy to avoid 
such complications is to not use excessive amounts of RNAi 
triggers and by applying “gentle” designs that promote their 
efficient processing. Recent progress in the enzymology of 
particularly Dicer processing44 and RNA-induced silencing 
complex loading45 provide guidelines for this.
In summary, advances in a range of enabling technolo-
gies have greatly enhanced the quality of RNAi therapeu-
tics science since 2008. This is in contrast to, and indeed 
was possibly encouraged by the recent criticisms of RNAi 
therapeutics.
IP, know-how, and trade secrets. The value that individual 
companies can derive from the above enabling technologies 
also depends on their ability to protect them by patents, also 
for licensing purposes, or on keeping them as trade secrets, 
thus maintaining their competitive advantage in areas that are 
critical for RNAi success and require deep technical know-
how. Because basic RNAi trigger structures are easily reverse 
engineered and are prone to inadvertent disclosure, seeking 
patent protection is a common strategy in RNAi triggers. One 
of the biggest changes in the strategic landscape in (synthetic) 
RNAi therapeutics since 2008 has been the disappearance 
of RNAi trigger IP with gate-keeping potential (Table 3). This 
is largely the result of the course the KL (claiming dsRNAs 
of wide size range) and Tuschl patent prosecutions (claiming 
the sweet-spot of dsRNA length and the 3′ overhang feature) 
have taken in the United States and Europe: the Tuschl I and 
KL patents are likely to be limited to therapeutically irrelevant 
methods of generating RNAi triggers (e.g., isolated RNA from 
enzymatic processing reactions in cell lysates-Tuschl I) or to 
structures of little potency (e.g., short dsRNAs held together 
by covalent chemical linkage-KL). Only the Tuschl II patent 
family continues to look strong in regards to one of the most 
desirable RNAi trigger structures, 19–21 bp dsRNAs with 3′ 
overhangs. Similarly, the Zamore patent series, recently chal-
lenged and upheld in the United States, broadly covers an 
influential  design  feature  (differential  thermodynamic  end-
stability), especially in Europe. Nevertheless, in both cases 
scientifically acceptable workarounds are available and their 
value primarily resides in maximizing RNAi trigger choice and 
reducing  discovery  cost.  The  disappearance  of  potentially 
gate-keeping RNAi trigger patents also had the effect of reduc-
ing the value of RNAi triggers for which the primary motivation 
had been to provide KL/Tuschl workaround solutions.
The situation is different in ddRNAi therapeutics where 
  following the apparent destruction of fundamental ddRNAi 
trigger  IP  as  a  result  of  the  Benitec–Nucleonics  conflict,  
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Benitec managed the unusual feat of getting its ddRNAi trig-
ger IP (“Graham patents”) widely reinstated in its original 
strength. However, as with any of the potentially fundamental 
patent applications covering RNAi triggers, its value is rapidly 
deteriorating given that the number of ddRNAi therapeutics 
that still have a chance of reaching commercialization by the 
time the IP expires (~2018 in the case of Graham) is shrink-
ing rapidly. What makes it difficult for companies to enforce 
and monetize such IP before drug approval and commercial-
ization is the Research Exemption which gives companies 
broad protection when utilizing patented matter as long as it 
is used in the process of obtaining regulatory approval.
This assumption, however, may be put to the test after 
ISIS  Pharmaceuticals  recently  sued  Santaris  on  RNaseH 
gapmer technology which ISIS claims to own and Santaris 
allegedly infringed upon by selling it in the course of their 
collaborations with Big Pharma. Absent a reinterpretation of 
the Research Exemption, however, the value of RNAi trig-
ger IP resides increasingly in fresher IP that covers more 
specific features such as the sequence of the 3′ overhang 
or thermodynamic design rules which may be scientifically 
desirable, but not indispensable. Further motivating compa-
nies to take licenses to RNAi trigger IP should be the need to 
ensure freedom-to-operate in a patent landscape that is get-
ting increasingly crowded by a number of narrower patents.
What is sometimes forgotten in the discussion of RNAi 
trigger-related IP is that with the exception of the latest RNAi 
trigger inventions, the value of IP related to basic RNAi trig-
ger structures in terms of market exclusivity is limited as RNAi 
therapeutics offers multiple IP opportunities downstream of 
the basic RNAi trigger structure which will set the clock for 
loss of market exclusivity and include the specific RNAi trig-
ger sequence or formulation.
In  contrast  to  RNAi  triggers,  a  much  higher  portion  of 
the  competitive  value  in  delivery  is  tied  up  in  the  form 
of trade secrets and know-how, the value of which typically 
scales with the complexity of a delivery technology: simple   
conjugates rely more on patent protection than difficult-to-
formulate nanoparticles. The value of delivery trade secrets 
is also illustrated by the fact that there has yet to be a generic 
version  of  a  nanoparticle-based  drug.46 This  should  be  a 
particularly attractive feature to the pharmaceutical industry 
which is currently in patent-cliff freefall. The importance of 
trade secrets and know-how in RNAi therapeutics is exempli-
fied by liposomal delivery where precise formulation ratios, 
the understanding of rational lipid design, and manufactur-
ing know-how has been the difference between technologies 
that fail to progress beyond the rodent-stage of development, 
and those that can be translated further into nonhuman pri-
mate and clinical studies. It is this know-how that allowed 
Tekmira to become a major player in RNAi therapeutics, but 
which Tekmira claims Alnylam, by taking advantage of its 
partner status and by inappropriately hiring former Tekmira 
employees, has violated in a series of deceptive and mali-
cious acts to enrich itself and marginalize Tekmira. On the 
other hand, the legal case also illustrates the dangers of a 
trade secret-dependent business model in an industry where 
partnering is essential, but where partners can often be your 
fiercest competitor.
BUSINESS DEVELOPmENT STRATEGIES
Small RNAi therapeutics innovator (“pure-play”) companies 
and  Big  Pharma  remain  the  industry’s  two  protagonists, 
although medium-sized pharmaceutical companies, includ-
ing those in Asian countries, have taken some of the space 
vacated by Big Pharma. The following section analyzes the 
strategies of pure-play RNAi innovator companies and RNAi 
asset buyers during the RNAi therapeutics backlash and pro-
vides business development suggestions going forward.
The pure-play perspective. The fate/response of first-gen-
eration pure-play RNAi therapeutics companies has been as 
diverse as their technical capabilities and motivations: some 
closed shop as investors lost faith in their science and busi-
ness practices (e.g., Nucleonics), while the survivors tried 
Table 3  Changes in strategic RNAi trigger IP landscape since 2008
Patent family Potential blocking threat 2008 Present status
Fire (US6506559, US7560438) All dsRNAs, although licensor (Carnegie 
Institute of Washington) pursued broad  
non-exclusive licensing strategy
Likely only useful for ex vivo delivery approaches
Kreutzer–Limmer (European only: 
EP1550719, EP1214945)
All dsRNAs from 15–49 bp (all useful  
RNAi triggers)
Never rose to prominence in US; in Europe, although ‘945 still 
potentially broad, K-L series likely to cover only “unusual”  
structures, such as 15 bp dsRNAs held together by covalent 
linkage
Tuschl I (US patent app 09/821832, 
10/255568; EP1309726)
All dsRNAs ~19–23 bp (sweet-spot of  
RNAi triggers)
Abandoned (US); limited to therapeutically irrelevant produc-
tion methods, e.g. fly lysates (Europe)
Tuschl II (US patent app 10/832432, 
10/832,248, 10/433050; US7056704, 
US7078196; EP1407044)
All 3′-overhang siRNAs from  
~18–24 bp
European patent still broadly covering valuable 3′ overhang 
feature, but opposition proceeding ongoing; US patents partly 
issued, partly examination ongoing; in both cases various 
objections raised especially in light of “Bass” and “Tuschl I”
Zamore (US US7750144; EP1633890) RNAi triggers enhanced by seminal  
thermodynamic end-stability design rule
Very broad claims issued in Europe (opposition filed); US 
claims useful, but can be worked around; however, presents 
uncertainty to most modified RNAi triggers
Graham (US6573099; EP1555317) ddRNAi gate-keeping US patent rejected  
in re-exam instigated by Nucleonics
Re-issued in US and issued in Europe with claims arguably 
covering most/all current clinical ddRNAi approaches; potential 
weakness: limitations in linker sequence as well as length and 
complementarity of dsRNA
Abbreviations: ddRNAi, DNA-directed RNA interference; dsRNA, double-stranded RNA; IP, intellectual property; RNAi, RNA interference; siRNA, small  
interfering RNA.Molecular Therapy–Nucleic Acids
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everything from focusing efforts on the achievement of key 
technical and product milestones to broadening their technol-
ogy offerings and merging with each other. Still, they, along 
with the few new entrants, are united by the hope that should 
RNAi therapeutics appetite return, for example as a result of 
the ongoing clinical dataflow, they will be well positioned to 
ride the wave of renewed enthusiasm. The following section 
discusses major business development themes in the pure-
play RNAi therapeutics space.
Shift from RNAi triggers to delivery. Unsurprisingly given 
the demands in the marketplace, there has been a shift in 
strategic  focus  of  RNAi  innovators  from  RNAi  triggers  to 
delivery. Silence Therapeutics for example, once competing 
with Alnylam for RNAi trigger customers, has repositioned 
itself as an RNAi delivery company, despite controlling some 
interesting RNAi trigger IP claiming blunt-ended dsRNAs and 
thermodynamic design rules. Alnylam, as indicated before, 
also realized the strategic value of delivery and aggressively 
moved  to  take  control  over  the  industry’s  most  advanced 
delivery platform, SNALP.
This strategic reorientation is vindicated by the deal activi-
ties since 2008 (Table 4). More than half of the most signifi-
cant deals contain delivery as its major component. Product 
licensing  deals  take  second  place  and,  only  then,  RNAi 
triggers third place. Delivery lends itself to business devel-
opment,  because  a  small  company  cannot  exploit  all  the 
therapeutic opportunities that a delivery solution for a given 
cell/tissue type would offer. Due to the numerous delivery 
offerings, including those from various non-RNAi companies 
hoping to capitalize on the delivery demand in RNAi, and the 
historically high failure rate of early-stage delivery technolo-
gies, only the fate of the companies with the most advanced 
delivery technologies, first and foremost SNALP (Tekmira) 
and  AtuPLEX  (Silence Therapeutics),  but  potentially  also 
sd-rxRNAs (RXi Pharmaceuticals) and Dynamic PolyConju-
gates (Arrowhead), may be in their own hands as it is clinical 
validation that most Big Pharma want to see before mak-
ing any new significant investments. It is therefore critical for 
these companies to focus their resources on these proof-
of-concepts, while the rest will have to keep advancing their 
technologies with high-quality research and hope that a new 
wave of RNAi enthusiasm will also lift their respective boats.
Diversification to cast a wider net for partnering. Instead 
of  focusing  on  reaching  clinical  or  late-preclinical  valida-
tion events, Marina Biotech has sought to escape the RNAi 
maelstrom  by  diversifying  its  offerings  away  from  RNAi 
therapeutics to become an oligonucleotide therapeutics one-
stop-shop. By this, it wants to take advantage of the quite 
healthy business activity around some of the non-RNAi oligo-
nucleotide technologies, especially microRNA therapeutics 
and antisense, and the fact that Big Pharma these days often 
views RNAi as one of a few RNA Therapeutics alternatives to 
go after the undruggable targets. Pfizer and Merck for exam-
ple have housed their RNAi therapeutics activities in “RNA 
therapeutics” units. The strategy of Marina may have been 
motivated by a failure to bring its RNAi platform technolo-
gies closer to the clinic. Regardless, it was certainly a bold 
move financially as it kept costs high at a time that capital in 
RNAi therapeutics quickly dried up. As a result, sharehold-
ers witnessed a ~99% drop in the share price since 2008. 
Moreover,  with  so  many  technologies,  yet  relatively  small 
workforce, such a strategy risks losing scientific depth and 
ultimately credibility.
Similar things can be said of the merger between Intradigm 
and Silence Therapeutics in early 2009, although in this case 
the one-stop-shop idea was pursued still within RNAi thera-
peutics. The combined company, however, soon gave up on 
the concept and instead channeled resources into delivery 
and the development of its lead clinical candidate, Atu027. 
RXi Pharmaceuticals meanwhile is a more complex case. 
On the one hand, RXi, once a diversified RNAi therapeutics 
company,  conducted  a  strategic  review  and  subsequently 
focused its RNAi activities on self-delivering rxRNAs and on 
entering a candidate based on the technology (RXI-109) into 
clinical development, thereby establishing itself as a leader 
in  local/localized  delivery.  The  company,  however,  finally 
decided to exit RNAi therapeutics altogether by spinning off 
the related assets in order to jump onto the therapeutic can-
cer vaccine bandwagon.
In general, in a capital-constraint environment where part-
nerships are increasingly geared towards the achievement of 
technical milestones, and with investors and potential collab-
orators expecting clinically relevant validation, diversification 
does not appear to be the right strategy for small pure-play 
companies. After all, it took Tekmira 500 person-years and 
over US$200M to turn a single technology, SNALP, into the 
prolific drug development engine it is today.
Product versus platform focus. Also outside of RNAi thera-
peutics, it is difficult these days to be a platform company with 
a relatively early-stage technology as this demands a good 
part of the investments to go into basic platform development 
work. Drug companies, however, are largely valued accord-
ing to their late-stage clinical pipeline with earlier-stage activ-
ities, especially preclinical research often commanding no 
to even negative values. Expeditiously advancing the most 
developed candidates has therefore become important in its 
own right, not just for the purpose of validating their underly-
ing technologies.
Alnylam and Quark Pharma are the companies with the 
most intense product focus. Alnylam in early 2011 launched 
the 5x15TM program that foresees the company to have five 
high-impact  orphan  drug  candidates  in  late-stage  clinical 
development by 2015. This was meant to help biotech inves-
tors rationalize a stock market capitalization of $500–600M 
(and $400M in cash) at the time which was difficult to sup-
port based on platform potential alone. In Quark’s case, two 
late and early phase II programs each, and one in phase I 
meant that it had little choice but spend its capital on its clini-
cal product candidates.
Virtual  RNAi  therapeutics  development.  Benitec  and 
Arrowhead Research responded to the RNAi therapeutics 
capital  contraction  by  adopting  virtual  drug  development 
models. This model has gained in popularity in the pharma-
ceutical industry and attempts to increase capital efficiency 
by outsourcing R&D activities to outside vendors to reduce 
fixed costs, avoid underutilization of assets, and maximize 
financial flexibility.
This model may work well when the goal is to develop one-
off clinical-stage compounds. It is doubtful, however, that it is 
an appropriate model for platform technology companies that  
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rely on scientific leadership to attract non-dilutive revenues 
from partnerships and licensing. In RNAi therapeutics, essen-
tially all deals these days (Table 4), except for the product-
specific ones, include a collaborative research component, 
illustrating the value pharmaceutical companies attach to the 
technical expertise of the platform company to ensure that 
the licensed IP is put to good use. Perhaps realizing that the 
inadequacy of the virtual model may have accounted for their 
failure to monetize its RONDEL delivery technology, Arrow-
head, with the acquisition of Roche’s RNAi assets including a 
40 plus research staff in Wisconsin, has started to reinvest in 
research. The timing, however, is also a gamble that animal 
spirits are about to return to RNAi therapeutics.
Pure-play  survival  guidelines.  The  equity  destruction  in 
Marina  Biotech  shows  that  pure-play  RNAi  therapeutics 
companies can only survive, i.e., be investable, if they can 
generate  non-dilutive  revenues.  The  licensing  of  platform 
technologies  and  product  candidates  obviously  represent 
the two main sources of such revenues. Other opportunities, 
however, such as Tekmira’s Ebola biodefense contract with 
the United States government also exist. Between US$70–
100M of such non-dilutive revenues was earned over the last 
3 years (Table 4, plus modest revenues from various unlisted 
and existing collaborations). This compares to ~US$1B for 
the same period before that.
Whether  these  numbers  can  return  to  healthier  levels 
depends largely on the results from the ongoing clinical stud-
ies with ALN-TTR01, ALN-PCS02, and Atu027. The sector 
can ill afford negative or inconclusive results because a con-
tinuation of the current drought would risk creating a large 
innovation  gap,  ultimately  to  the  detriment  of  everybody 
involved, small and big. In this period of transition, financial 
arrangements such as by Benitec with La Jolla Cove Inves-
tors,  Marina  Biotech  with  Lincoln  Park  Capital  Fund,  and 
Arrowhead Research, also with Lincoln Park Capital Fund, 
can provide pure-play companies with funding security, yet 
the flexibility to terminate these dilutive arrangements once 
better sources of capital present themselves.
Some of the funding shortfall may be compensated for by 
investments from pharmaceutical companies from Japan and 
the emerged economies surrounding it (China, Korea, Singa-
pore). The shift of innovative drug development to the East will 
not stop at RNAi therapeutics, and although Roche’s decision 
has also given investors there some pause, being early-stage 
and innovation-driven, RNAi therapeutics is still an attractive 
technology by which these societies can further move up the 
economic value chain, also in anticipation of the increasing 
number of citizens that will have access to such medicines. 
First-generation RNAi therapeutics innovator companies from 
the West can capitalize on this demand by monetizing their 
RNAi assets for markets that, for geographic and cultural rea-
sons, are of less strategic interest to them.
The Big Pharma perspective. Despite its $2.5–3B invested 
in RNAi therapeutics in 2005–08, Big Pharma has yet to bring 
a single such compound into clinical development. It is thus 
no surprise that RNAi therapeutics has become a bad career 
strategy in Big Pharma, and it explains why the bar for new 
investments has increased considerably. Roche, Pfizer, and 
Abbott  Labs  have  terminated  in-house  RNAi  therapeutics 
development altogether, others like Merck and AstraZeneca 
have reduced their activities.
There are a number of explanations for this track record 
und unhappiness. In retrospect, the RNAi trigger IP licenses 
which have since lost much of their strategic value account 
for approximately half of the waste. Big Pharma may also 
have relied too much on assurances by pure-play companies 
that delivery technologies were more mature than they really 
were. It is interesting for example that Roche’s Factor VII pat-
ent application (WO 2010/055041) features Alnylam’s “lipi-
doid” technology for the rodent studies, but then switched to 
Tekmira’s SNALP liposomes for the nonhuman primate part 
of the patent application. Major contributors to waste were 
also platform development strategies that may work for small 
molecules, but go against the scientific grain of RNAi thera-
peutics. This includes selecting indications based on sales 
predictions  and  therapeutic  franchises  rather  than  based 
on in which cell/tissue type knockdown can be technically 
achieved; similarly failing to follow the science in pursuing 
delivery based on patient convenience; and finally putting 
the cart before the horse by first focusing on developing clini-
cal  pharmacology  assays  and  optimizing  manufacturing33 
instead of on overcoming the actual rate-limiting challenges. 
This paradox is symbolized by AstraZeneca’s 2011 partner-
ship with PTC therapeutics in RNA-targeted therapeutics, 
which  aims  at  modulating  RNA  processing  for  anticancer 
therapy  using  orally  available  small  molecules,  not  oligo-
nucleotides. To some extent Big Pharma needs to trust that 
following the science maximizes the chance of developing 
the innovative, high-impact medicines for diseases of high 
unmet medical need which have become the profit centers 
of the industry and which RNAi therapeutics, as a genetic 
medicine, is ideally positioned to address.
Despite these failures, most Big Pharma companies either 
still pursue RNAi therapeutics or at least follow it closely, 
understanding that it is more a question of when and not of 
whether RNAi therapeutics will become a major new drug 
development engine or not. The causes of their failure imme-
diately suggest how RNAi asset buyers in general, not only 
Big Pharma, can improve their RNAi therapeutics odds. Fun-
damentally, it needs to be questioned whether Big Pharma 
is the right place for RNAi innovation. While the acquisitions 
of established RNAi therapeutics research groups allowed 
Merck and Roche to be the source of at least some innova-
tion, efforts to grow RNAi therapeutics platform capabilities 
from the ground up internally (e.g., Abbott, GSK, Novartis) or 
after acquiring non-RNAi oligonucleotide technologies (e.g., 
Pfizer) have been less successful. In some cases, internal 
groups  may  also  have  the  damaging  effect  of  posing  an 
obstacle to taking (more capital-efficient) advantage of supe-
rior outside innovation in favor of home-brew versions of the 
same technologies (e.g., liposomal delivery).
When shopping for RNAi technologies, it is the responsibil-
ity of buyers to deeply familiarize themselves with the field to 
spot the few good technologies in a sea of questionable offer-
ings. Purchase decisions should also not be primarily moti-
vated by what their peers are doing. As the 2005–08 bubble 
illustrates, such herd instinct can lead to costly mistakes, and 
in this part of the business cycle may mean the failure to take 
advantage of the severely depressed asset prices. In fact,  
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from a financial risk-reward perspective, this may be the best 
time ever to become involved in RNAi therapeutics develop-
ment. This also applies to pharmaceutical companies and 
economic policy makers in the emerged economies which 
can transfer the most promising technologies for a fraction of 
what it cost to develop them.
BUSINESS OUTLOOK
As noted before, the results from the ongoing ALN-TTR01 
and ALN-PCS02 SNALP-based clinical studies will have a 
major impact on the RNAi therapeutics business climate for at 
least the next 2 years. Data from the AtuPLEX-based Atu027 
trial has the potential to amplify the SNALP-driven return in 
bullishness, but because the AtuPLEX-based pipeline is still 
thin, is unlikely to carry a sentiment shift by itself. This also 
applies to any unexpected positive data from Quark/Pfizer’s 
phase II study in wet age-related macular edema (patient 
recruitment completed), as like the rest of Quark’s pipeline, 
this candidate does not have platform character.
With capital spread thin in the industry, negative results 
could  have  devastating  consequences  for  companies  in 
need of financing. On the other hand, operational costs have 
been reduced already and valuations fallen so deep, that 
should the nascent recovery that set in with the ALN-VSP02 
and Atu027 data presentations at ASCO 2011 find confirma-
tion later this year (2011), being invested now could be quite 
profitable. Despite the more linear advance of the science, 
the business of RNAi therapeutics is thus likely to remain a 
cyclical one.
The shift in Big Pharma’s involvement in RNAi therapeu-
tics  from  in-house  platform  development  to  product-spe-
cific licensing and co-development is likely to persist, also 
because of the structural changes in the industry towards 
the outsourcing of research. Their place may be taken by 
medium-sized pharmaceutical companies and new players 
from  the  emerged  economies,  governments,  and  compa-
nies, which view RNAi therapeutics as a potentially disrup-
tive technology where they still have the chance to become 
leaders and thereby establish themselves in innovative drug 
development.
Business in ddRNAi therapeutics is somewhat uncoupled 
from RNAi therapeutics triggered by synthetic RNAi triggers, 
mainly due to the technical differences which make it more 
similar to traditional gene therapy. It is, however, set to gain 
traction, not just because of numerous supporting preclinical 
data,15,24,25 but also because of it being part of the gene ther-
apy field which is experiencing a revival47 following a boom 
and bust similar to what RNAi therapeutics has just gone 
through. But whatever the latest trends in the pharmaceuti-
cal industry, healthcare systems, and global economy, the 
best advice to all participants in RNAi therapeutics is to oper-
ate on the assumption that in 5–10 years, when first RNAi 
therapeutics  should  be  commercialized,  innovative  drugs 
that help the lives of seriously ill people will more likely than 
not make a profit.
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